Advertisement
Australia markets close in 1 hour 47 minutes
  • ALL ORDS

    7,851.00
    -86.50 (-1.09%)
     
  • ASX 200

    7,589.40
    -93.60 (-1.22%)
     
  • AUD/USD

    0.6523
    +0.0000 (+0.00%)
     
  • OIL

    83.85
    +0.28 (+0.34%)
     
  • GOLD

    2,347.40
    +4.90 (+0.21%)
     
  • Bitcoin AUD

    98,517.82
    +194.09 (+0.20%)
     
  • CMC Crypto 200

    1,387.64
    +5.06 (+0.37%)
     
  • AUD/EUR

    0.6082
    +0.0009 (+0.14%)
     
  • AUD/NZD

    1.0952
    -0.0006 (-0.05%)
     
  • NZX 50

    11,817.24
    -129.19 (-1.08%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,626.75
    +342.21 (+1.98%)
     
  • NIKKEI 225

    37,868.34
    +239.86 (+0.64%)
     

Apiam Animal Health First Half 2023 Earnings: EPS: AU$0.017 (vs AU$0.013 in 1H 2022)

Apiam Animal Health (ASX:AHX) First Half 2023 Results

Key Financial Results

  • Revenue: AU$93.7m (up 25% from 1H 2022).

  • Net income: AU$2.90m (up 66% from 1H 2022).

  • Profit margin: 3.1% (up from 2.3% in 1H 2022). The increase in margin was driven by higher revenue.

  • EPS: AU$0.017 (up from AU$0.013 in 1H 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Apiam Animal Health Earnings Insights

Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

ADVERTISEMENT

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Apiam Animal Health that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here